COMBINATION and conjugates of monoclonal antibodies to interferon and their use in therapy of HER2-positive human tumors

摘要

1. A preparation for the treatment of HER2-positive tumors, characterized in that it comprises a monoclonal antibody, trastuzumab, and interferon effective kolichestvah.2. The drug for treatment of HER2-positive tumors, characterized in that it comprises an effective amount of a conjugate of the monoclonal antibody trastuzumab with interferon sewn together chemically putem.3. The preparation according to claim. 1, characterized in that it comprises a pharmaceutically acceptable nositel.4. The preparation according to claim. 1, characterized in that the interferon is used as interferon-α.5. The preparation according to claim. 1, characterized in that the interferon is used as interferon-β.6. The preparation according to claim. 1, characterized in that the interferon is used as interferon-ω.7. The preparation according to claim. 1, characterized in that the interferon is used as interferon-τ.8. The preparation according to claim. 1, characterized in that the interferon is used as interferon-γ.9. The preparation according to claim. 2, characterized in that it comprises a pharmaceutically acceptable nositel.10. The preparation according to claim. 2, characterized in that the interferon is used as interferon-α.11. The preparation according to claim. 2, characterized in that the interferon is used as interferon-β.12. The preparation according to claim. 2, characterized in that the interferon is used as interferon-ω.13. The preparation according to claim. 2, characterized in that the interferon is used as interferon-τ.14. The preparation according to claim. 2, characterized in that the interferon is used as interferon-γ.15. The preparation according to claim. 2, characterized in that the interferon trastuzumab crosslinked chemically by heterobifunctional nonpeptidic linkera.16. The preparation according to claim. 2, characterized in that t;1。一种治疗HER2阳性肿瘤的制备物，其特征在于它包含单克隆抗体、曲妥珠单抗和干扰素有效kolichestvah.2。治疗HER2阳性肿瘤的药物，其特征在于它包括有效量的单克隆抗体曲妥珠单抗与干扰素结合物，用化学方法缝合在一起。根据索赔准备。1，其特征在于它包括药学上可接受的鼻。4。根据索赔准备。1，干扰素作为干扰素α5。根据索赔准备。1、干扰素作为干扰素β6。根据索赔准备。1，干扰素被用作干扰素ω。7。根据索赔准备。1，干扰素被用作干扰素-γ。8。根据索赔准备。1，干扰素作为干扰素-γ。9。根据索赔准备。2，其特征在于它包括药学上可接受的鼻孔。根据索赔准备。2，干扰素作为干扰素α11。根据索赔准备。2、干扰素作为干扰素β12。根据索赔准备。2，干扰素被用作干扰素ω。13。根据索赔准备。2，干扰素被用作干扰素-γ。14。根据索赔准备。2，干扰素作为干扰素-γ。15。根据索赔准备。2，其特征在于，干扰素-曲妥珠单抗通过异构化的非肽键交联。根据索赔准备。2，其特征在于